Cipla receives USFDA nod for arformoterol tartrate inhalation solution

The solution had US sales of approximately $438 million for the 12-month period ending April 2021.

The drug major said that it has received final approval for its abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution 15 mcg / 2 mL from the United States Food and Drug Administration (USFDA).

The solution is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.'s Brovana.

Brovana is a long-acting beta-2 adrenergic agonist (beta-2 agonist) indicated for the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

According to IQVIA (IMS Health), Brovana had US sales of approximately $438 million for the 12-month period ending April 2021.

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets.

On a consolidated basis, the company's net profit surged 71.5% to Rs 415.51 crore on 6.6% rise in net sales to Rs 4,584.88 crore in Q4 FY21 over Q4 FY20.

The scrip rose 0.47% to currently trade at Rs 960.15 on the BSE. It traded in the range of 955.65 and 965.80 so far during the day.

Powered by Capital Market - Live News